Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 40

Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 121

WellCare Health Adds Universal American for $800 Million

by | Nov 22, 2016 7:26 pm | Managed Care

WellCare Health Plan (NYSE: WCG) breathed a little life into the lethargic Managed Care sector, which has experienced a lull in M&A this year. WellCare provides government-sponsored managed care services, and its target, Universal American Corp. (NYSE: UAM), provides health insurance and managed care products and services to Medicare and Medicaid customers in the United States. The purchase price is $800 million, or $10.00 per share, representing a 34% premium to Universal American’s 60-day volume-weighted average closing stock price as of November 16, 2016, and includes the retirement of Universal American’s preferred shares and its convertible debt. WellCare expects the... Read More »

CROs Are Back, Many with Specialties

by | Nov 18, 2016 4:12 pm | Other Services, Private Equity

We’ve documented the increase in biotechnology acquisitions and license deals by pharmaceutical companies in previous posts. But the impact of pharma’s move away from in-house R&D has benefited other sectors of the healthcare industry, particularly clinical research organizations (CROs). For those outside the technology side of healthcare, CROs provide outsourced research services to the pharmaceutical, biotechnology, and medical device industries on a contract basis. Through mid-November, we’ve seen an increase of 325% in deal volume for CROs, compared with the year before. In 2015, just five deals for these targets were announced. So far this year, 17 are on the... Read More »

November Sees a Surge in Lab Deals

by | Nov 17, 2016 8:00 am | Laboratories, MRI & Dialysis, Private Equity

Four deals in our Laboratories, MRI & Dialysis sector have been announced in the first half of November. That much activity constitutes a surge for this sector, which now stands at 39 deals through all of 2016. With only six weeks left in the year, it seems unlikely that this sector will surpass 2015’s total of 52 deals. On November 1st, Vital Images, Inc., a subsidiary of Toshiba Medical Systems Group, acquired Karos Health for an undisclosed price. Karos Health provides standards-based clinical imaging exchange and cross-enterprise workflow and diagnostic imaging solutions. The combined technologies provide a customer-centric, modular platform that allows hospital systems to solve a... Read More »

What U.S. Hospitals Are Acquiring in 2016

by | Nov 16, 2016 8:45 pm | Behavioral Health Care, eHealth, Home Health & Hospice, Hospitals, Laboratories, MRI & Dialysis, Long-Term Care, Managed Care, Other Services, Physician Medical Groups

Hospital acquisitions have surged since the Affordable Care Act was passed in 2010. That year, 76 deals were announced, with a U.S. hospital or health system as a target. By 2012, 107 transactions were recorded for hospital targets, and that still stands as the highest number of deals per year. Only 2015 came close, with 102 hospital transactions. Through mid-November, there have been 79 deals announced with U.S. hospitals or health systems as the target. But what are U.S. hospitals acquiring for their own financial health? Other hospitals or health systems make up the majority of targets every year, of course.  So far this year, through mid November, 66 transactions... Read More »

Boston Scientific Seeks Out Portfolio Acquisitions

by | Nov 15, 2016 4:57 pm | Medical Devices

Earlier this year, Boston Scientific Corporation (NYSE: BSX) acquired two companies: Cosman Medical Inc. to strengthen its neuromodulation business and EndoChoice Holdings Inc. to strengthen its pathology services and imaging technologies. Since then, the medical device giant has toned down its acquiring habits with two asset/portfolio purchases in November. On November 3, 2016, the company acquired the LumenR™ Tissue Retractor System from LumenR LLC. It is currently in development for use during endoscopic resection of lesions in the colon, esophagus or stomach. Boston Scientific will conduct additional development and evaluation of the system prior to commercialization. On November 15,... Read More »

Biotech Boomed Even Before Trump’s Election

by | Nov 11, 2016 4:31 pm | Biotechnology, Pharmaceuticals

Now that Donald Trump has transitioned from presidential candidate to president-elect, his pro-business views have cheered many deal makers. His “repeal and replace” pronouncements regarding the Affordable Care Act have chilled some areas of the healthcare market, but others are thriving. Biotechnology is one sector that was already experiencing a boom in mergers and acquisitions, prior to November 8. Third-quarter deal volume surged 58%, to 52 transactions. Sixteen deals were recorded in October 2016, and in the first two weeks of November, 12 are already in our database. Ten of those are license agreements, as pharmaceutical companies swoop in to claim promising product... Read More »

Rehabilitation Deals Still Rising, Thanks to Private Equity

by | Nov 10, 2016 8:57 pm | Private Equity, Rehabilitation

The year isn’t over, and the Rehabilitation sector has already equaled last year’s deal total. Thirty-three deals have been made public through November 11, 2016, compared with 33 in all of 2015. Spending is a bit lower at this point in 2016, at $623 million, down 21% compared with last year’s annual total of $799 million. That may change, depending on the number of deals that disclose prices between now and the end of the year. Four private equity firms have made acquisitions in this sector in 2016. Even though no price was disclosed, the largest was probably from Advent International, which acquired ATI Physical Therapy, a platform company based in Bolingbrook,... Read More »

NASH-Driven Deals Pile Up

by | Nov 9, 2016 5:06 pm | Biotechnology, Pharmaceuticals

On November 10, 2016, Bristol-Meyers Squibb (NYSE: BMY) purchased the exclusive worldwide rights to develop and commercialize Nitto Denko Corporation’s (TYO: 6988) investigational siRNA, which includes Nitto’s lead asset ND-L02-s0201. Nitto’s lead asset ND-L02-s0201 is currently in a five-week open-label Phase 1b study in patients with advanced fibrosis (F3-F4c) due to non-alcoholic steatohepatitis (NASH) or hepatitis C. Nitto Denko received a $100 million upfront payment as part of the license agreement, and it is not the first company to cash in on its product candidates for the possible treatment of NASH. NASH is characterized by fatty infiltration of the liver not caused by alcohol,... Read More »